bioAffinity Technologies, Inc. - BIAF Net earnings per share for the last 12 months

Public company logo of bioAffinity Technologies Inc. (BIAF)

bioAffinity Technologies (BIAF) is implementing the non-invasive CyPath Lung method for early-stage lung cancer detection. The 12-month YoY percentage change in EPS demonstrates growth driven by AI-powered cytometry robotics and steady diagnostic laboratory utilization. The current mark of 87.10 captures this metric, confirming the fundamental resilience of earnings per share.

bioAffinity Technologies, Inc. (BIAF): Earnings per share for the last twelve months from 02/11/2024 to 11/13/2026

bioAffinity - analytical breakdowns and key metrics (BIAF)

- share price and consensus valuation forecast:
Share Price bioAffinity Technologies|BIAF - Analyst Consensus Forecast
- issuer market value details:
Market Valuation bioAffinity Technologies Inc.|BIAF - Enterprise Value
- book capitalization data:
Net Asset Value per Share bioAffinity Technologies|BIAF - Company Book Value|Market Value to Book Value bioaffinitytech.com|BIAF - Company Total Assets
- company total debt and liquidity indicators:
Debt to Equity bioAffinity Technologies|BIAF - Long-Term Debt to Capital|Short-Term Debt to Capital Coefficient bioAffinity Technologies|BIAF - Company Debts|Debts to Book Value bioAffinity Technologies Inc.|BIAF - Company Long-Term Debts|Company Short-Term Debts bioAffinity Technologies|Critical Liquidity Ratio bioaffinitytech.com
- net income and valuation ratios data:
BIAF - Net Profit|Forward Earnings bioAffinity Technologies|BIAF - P/E Multiple|Market Cap to Projected Earnings bioAffinity Technologies|BIAF - Price/Earnings to Growth Ratio|Enterprise Value to Operating Income Before Depreciation bioAffinity Technologies Inc.|BIAF - Operating profit EBITDA|Net earnings per share for the last four quarters bioAffinity Technologies|BIAF - Net earnings per share for the last 12 months|Year-over-year earnings per share growth rate for the last twelve months bioaffinitytech.com|BIAF - Net earnings per share growth this year|Expected net earnings per share growth next year bioAffinity Technologies
Initial company analysis:BIAF, bioAffinity Technologies, Inc.
Flagship merchandise of bioAffinity Technologies, Inc.

Investors utilize this indicator to stress-test the resilience of earnings trends. bioAffinity Technologies (BIAF) is strengthening its position in lung cancer diagnostics through its unique sputum analysis platform. The annual shift in EPS TTM measures the percentage change in net income per share over a rolling year. This metric reflects the efficiency of monetizing the company's technological advantage and pricing power. The growing trend confirms the scalability of the business.

Competitor analysis for bioAffinity Technologies

AVBP (ArriVent BioPharma Inc) - Earnings per share for the last 12 months|LTRN: Net earnings per share (EPS TTM)|Net earnings per share for the last 12 months eEFFECTOR Therapeutics, Inc.